Thromb Haemost 2008; 99(02): 295-304
DOI: 10.1160/TH07-08-0508
Theme Issue Article
Schattauer GmbH

Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data

Michael Hughes
1   National Collaborating Centre for Chronic Conditions, Royal College of Physicians, London, UK
,
Gregory Y. H. Lip
1   National Collaborating Centre for Chronic Conditions, Royal College of Physicians, London, UK
2   University Department of Medicine, City Hospital, Birmingham, England, UK
,
on behalf of the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care › Author Affiliations
Further Information

Publication History

Received: 17 August 2007

Accepted after major revision: 16 January 2007

Publication Date:
24 November 2017 (online)

Summary

The risk of stroke in atrial fibrillation (AF) needs to be assessed in each patient to determine the clinical and cost-effectiveness of thromboprophylaxis, with the aim of appropriate use of antithrombotic therapy. To achieve this, stroke risk factors in AF populations need to be identified and stroke risk stratification models have been devised on the basis of these risk factors. In this article, we firstly provide a systematic review of studies examining the attributable stroke risk of various clinical, demographic and echocardiographic patient characteristics in AF populations. Secondly, we performed a systematic review of published stroke risk stratification models, in terms of the results of the review of stroke risk factors and their ability to accurately discriminate between different levels of stroke risk. Thirdly, we review the health economic evidence relating to the cost-effectiveness of anticoagulation and antiplatelet therapy as thromboprophylaxis in AF patients. The studies included in the systematic review of stroke risk factors identified history of stroke or TIA, increasing age, hypertension and structural heart disease (left-ventricular dysfunction or hypertrophy) to be good predictors of stroke risk in AF patients. The evidence regarding diabetes mellitus, gender and other patient characteristics was less consistent. Three stroke risk stratification models were identified that were able to discriminate between different categories of stroke risk to at least 95% accuracy. Few models had addressed the cumulative nature of risk factors where a combination of risk factors would confer a greater risk than either factor alone. In patients at high risk of stroke, anticoagulation is cost effective, but not for those with a low risk of stroke. With the evidence available for stroke risk factors and the various alternative stroke risk stratification models, a review of these models in terms of the evidence on which they are devised and their performance in representative AF populations is important. The appropriate administration of thromboprophylaxis in AF patients would need to balance the risks and benefits of antithrombotic therapy with its cost-effectiveness.

 
  • References

  • 1 Benjamin EJ, Wolf PA, D'Agostino RB. et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-952.
  • 2 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
  • 3 Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis. Thromb Res 2006; 118: 321-333.
  • 4 Cantley P, McKinstry B, Macaulay D. et al. Atrial fibrillation in general practice: how useful is echocardiography in selection of suitable patients for anticoagulation?. Br J Gen Pract 1999; 49: 219-220.
  • 5 Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 2001; 37: 691-704.
  • 6 National Institute for Health and Clinical Excellence. Atrial fibrillation:. National clinical guideline for management in primary and secondary care.. 2006. London: National Institute for Health and Clinical Excellence.;
  • 7 Fuster V, Ryden LE, Cannom DS. et al. ACC/AHA/ ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006; 27: 1979-2030.
  • 8 National Institute for Clinical Excellence. Guideline Development Methods. Information for National Collaborating Centres and Guideline Developers.. 2004. London: National Institute for Clinical Excellence.;
  • 9 Miyasaka Y, Tsuji H, Tokunaga S. et al. Mild mitral regurgitation was associated with increased prevalence of thromboembolic events in patients with nonrheumatic atrial fibrillation. Int J Cardiol 2000; 72: 229-233.
  • 10 Laupacis A, Boysen G, Connolly S. et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Int Med 1994; 154: 1449-1457.
  • 11 Hart RG, Pearce LA, McBride R. et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30: 1223-1229.
  • 12 The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. J Am Geriat Soc 1998; 279: 1273-1277.
  • 13 Hart RG, Pearce LA, Rothbart RM. et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000; 35: 183-187.
  • 14 Wang TJ, Massaro JM, Levy D. et al. A risk score for predicting stroke or death in individuals with newonset atrial fibrillation in the community: the Framingham Heart Study. J Am Med Assoc 2003; 290: 1049-1056.
  • 15 Stollberger C, Chnupa P, Abzieher C. et al. Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. Clin Cardiol 2004; 27: 40-46.
  • 16 van Latum JC, Koudstaal PJ, Venables GS. et al. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. Stroke 1995; 26: 801-806.
  • 17 Petersen P. Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Arch Int Med 1990; 150: 819-821.
  • 18 Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Int Med 1992; 116: 1-5.
  • 19 Nakagami H, Yamamoto K, Ikeda U. et al. Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. Am Heart J 1998; 136: 528-532.
  • 20 Cabin HS, Clubb KS, Hall C. et al. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol 1990; 65: 1112-1116.
  • 21 Inoue H, Atarashi H. Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation. Am J Cardiol 2000; 86: 852-855.
  • 22 Moulton AW, Singer DE, Haas JS. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: A case-control study. Am J Med 1991; 91: 156-161.
  • 23 Aronow WS, Gutstein H, Hsieh FY. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. Am J Cardiol 1989; 63: 366-367.
  • 24 Aronow WS, Ahn C, Kronzon I. et al. Risk factors for new thromboembolic stroke in patients ≤62 years of age with chronic atrial fibrillation. Am J Cardiol 1998; 82: 119-121.
  • 25 Ezekowitz MD, Laupacis A, Boysen G. et al. Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch Int Med 1998; 158: 1316-1320.
  • 26 Pearce LA. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Int Med 1992; 116: 6-12.
  • 27 Seidl K, Hauer B, Schwick NG. et al. Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol 1998; 82: 580-583.
  • 28 Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis 1995; 5: 147-157.
  • 29 Laupacis A, Albers G, Dalen J. et al. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114 (Suppl. 05) 579S-589S.
  • 30 Fuster V, Ryden LE, Asinger RW. et al. ACC/AHA/ ESC Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38: 1266i-1266lxx.
  • 31 Singer DE, Albers GW, Dalen JE. et al. Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 429S-456S.
  • 32 Lip GY, Lowe GD. ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. Br Med J 1996; 312: 45-49.
  • 33 van Walraven C, Hart RG, Wells GA. et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Int Med 2003; 163: 936-943.
  • 34 Gage BF, Waterman AD, Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864-2862.
  • 35 Gage BF, van Walraven C, Pearce L. et al. Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287-2292.
  • 36 Pearce LA, Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med 2000; 109: 45-51.
  • 37 Go AS, Hylek EM, Chang Y. et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. J Am Med Assoc 2003; 290: 2685-2692.
  • 38 Eckman MH, Levine HJ, Salem DN. et al. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Chest 1998; 114 (Suppl. 05) 699S-714S.
  • 39 Caro JJ, O'Brien JA, Klittich W. et al. The economic impact of warfarin prophylaxis in nonvalvular atrial fibrillation. Dis Management Clin Outcomes 1997; 1: 54-60.
  • 40 Gustafsson C, Asplund K, Britton M. et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. Br Med J 1992; 305: 1457-1460.
  • 41 Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke 1998; 29: 1827-1832.
  • 42 Gage BF, Cardinalli AB, Albers GW. et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. J Am Med Assoc 1995; 274: 1839-1845.
  • 43 Desbiens NA. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis. J Am Geriat Soc 2002; 50: 863-869.
  • 44 Thomson R, Parkin D, Eccles M. et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000; 355: 956-962. Erratum in Lancet 2000 355: 1466.
  • 45 The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Int Med 1998; 128: 639-647.
  • 46 Chang YJ, Ryu SJ, Lin SK. Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation. Cerebrovasc Dis 2002; 13: 16-20.
  • 47 Lip GY, Lane D, Van Walraven C. et al. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006; 37: 2294-300. Erratum in Stroke 2006 37:2444.
  • 48 Hughes M, Lip GY. on behalf of the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulationrelated bleeding complications in patients with atrial fibrillation: a systematic review. Q J Med 2007; 100: 599-607.
  • 49 Hylek EM, Evans-Molina C, Shea C. et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
  • 50 Mant J, Hobbs FD, Fletcher K. et al. BAFTA investigators; Midland Research Practices Network (Mid-ReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
  • 51 Lakshminarayan K, Solid CA, Collins AJ. et al. Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). Stroke 2006; 37: 1969-1974.
  • 52 Siu CW, Jim MH, Ho HH. et al. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. Chest 2007; 132: 44-49.
  • 53 Flaker GC, Belew K, Beckman K. et al. AFFIRM Investigators. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149: 657-663.